NNOX vs. CDRE, INMD, BLFS, RXST, AORT, MDXG, LQDA, PLSE, EMBC, and FNA
Should you be buying Nano-X Imaging stock or one of its competitors? The main competitors of Nano-X Imaging include Cadre (CDRE), InMode (INMD), BioLife Solutions (BLFS), RxSight (RXST), Artivion (AORT), MiMedx Group (MDXG), Liquidia (LQDA), Pulse Biosciences (PLSE), Embecta (EMBC), and Paragon 28 (FNA). These companies are all part of the "medical equipment" industry.
Nano-X Imaging vs.
Nano-X Imaging (NASDAQ:NNOX) and Cadre (NYSE:CDRE) are both small-cap business services companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, community ranking, analyst recommendations, earnings, media sentiment, risk, institutional ownership, valuation and profitability.
Cadre has a net margin of 6.34% compared to Nano-X Imaging's net margin of -465.38%. Cadre's return on equity of 12.88% beat Nano-X Imaging's return on equity.
Nano-X Imaging currently has a consensus price target of $17.50, indicating a potential upside of 140.38%. Cadre has a consensus price target of $39.75, indicating a potential upside of 3.09%. Given Nano-X Imaging's stronger consensus rating and higher possible upside, equities research analysts plainly believe Nano-X Imaging is more favorable than Cadre.
21.5% of Nano-X Imaging shares are owned by institutional investors. Comparatively, 44.0% of Cadre shares are owned by institutional investors. 7.7% of Nano-X Imaging shares are owned by company insiders. Comparatively, 37.0% of Cadre shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Nano-X Imaging has a beta of 1.97, suggesting that its share price is 97% more volatile than the S&P 500. Comparatively, Cadre has a beta of 1.24, suggesting that its share price is 24% more volatile than the S&P 500.
Cadre has higher revenue and earnings than Nano-X Imaging. Nano-X Imaging is trading at a lower price-to-earnings ratio than Cadre, indicating that it is currently the more affordable of the two stocks.
Nano-X Imaging received 14 more outperform votes than Cadre when rated by MarketBeat users. Likewise, 71.43% of users gave Nano-X Imaging an outperform vote while only 55.17% of users gave Cadre an outperform vote.
In the previous week, Cadre had 1 more articles in the media than Nano-X Imaging. MarketBeat recorded 2 mentions for Cadre and 1 mentions for Nano-X Imaging. Nano-X Imaging's average media sentiment score of 1.09 beat Cadre's score of 0.27 indicating that Nano-X Imaging is being referred to more favorably in the media.
Summary
Cadre beats Nano-X Imaging on 11 of the 18 factors compared between the two stocks.
Get Nano-X Imaging News Delivered to You Automatically
Sign up to receive the latest news and ratings for NNOX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nano-X Imaging Competitors List
Related Companies and Tools
This page (NASDAQ:NNOX) was last updated on 2/1/2025 by MarketBeat.com Staff
